Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma

Authors :: C. Kunz
M. Thiemann
C. Gieffers
H. Fricke
Wolfgang Wick
B. Wiestler
J. Sykora
C. Merz
Source :: European Journal of Cancer. 61:S200
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Cancer Research
APG101
Cd95 ligand
Oncology
Response to therapy
CpG site
Chemistry
medicine
Cancer research
Differential Methylation
medicine.disease
Glioblastoma

Full Text Access

Tools